Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

41 42 Next >

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent

October 26, 2023

Via Investor Brand Network

Topics Intellectual Property

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

October 26, 2023

From Cybin Inc.

Via Business Wire

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program

October 25, 2023

Via Investor Brand Network

Topics Intellectual Property

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

October 25, 2023

From Cybin Inc.

Via Business Wire

Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics ↗

October 23, 2023

Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.

Via Benzinga

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector

October 23, 2023

Via Investor Brand Network

Topics Intellectual Property

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

October 23, 2023

From Cybin Inc.

Via Business Wire

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business ↗

October 20, 2023

Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.

Via Benzinga

Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement ↗

October 18, 2023

Short-acting psychedelics biotech Small Pharma Inc.

Via Benzinga

Small Pharma Obtains Final Order Approving Arrangement

October 17, 2023

From Cybin Inc.

Via Business Wire

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates ↗

October 13, 2023

Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.

Via Benzinga

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting

October 13, 2023

Via Investor Brand Network

Cybin Announces Results of Annual and Special Meeting of Shareholders

October 12, 2023

From Cybin Inc.

Via Business Wire

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit

October 06, 2023

Via Investor Brand Network

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

October 06, 2023

From Cybin Inc.

Via Business Wire

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

October 04, 2023

Via Investor Brand Network

Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit

October 04, 2023

From Cybin Inc.

Via Business Wire

Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment ↗

October 03, 2023

Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the

Via Benzinga

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares ↗

October 03, 2023

NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management...

Via Benzinga

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort

October 03, 2023

Via Investor Brand Network

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

October 03, 2023

From Cybin Inc.

Via Business Wire

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study

September 27, 2023

Via Investor Brand Network

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

September 27, 2023

From Cybin Inc.

Via Business Wire

Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression ↗

September 26, 2023

Clinical-stage psychedelics biotech Cybin Inc.

Via Benzinga

Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results ↗

September 26, 2023

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

Via Benzinga

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.